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Abstract
The purpose of  this study was to assess the prognostic value of  programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell 
carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embed-
ded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ≥1% of  staining. Histopatho-
logical characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free 
survival (RFS) stratified by PD-L1 status were estimated using the Kaplan–Meier method. Median age was 58 years and median follow-up 
was 40 months. Non-ccRCC subtypes included sarcomatoid (n = 9), rhabdoid (n = 6), medullary (n = 2), Xp11.2 translocation (n = 2), 
collecting duct (n = 1), papillary type I (n = 11), and papillary type II (n = 14). PD-L1 positivity was noted in nine (20%) patients. PD-L1 
positivity was significantly associated with higher Fuhrman nuclear grade (P = 0.048) and perineural invasion (P = 0.043). Five-year CSS 
was 73.2 and 83% for PD-L1 positive and negative tumors, respectively (P = 0.47). Five-year RFS was 55.6 and 61.5% for PD-L1 positive 
and negative tumors, respectively (P = 0.58). PD-L1 was expressed in a fifth of  non-ccRCC cases and was associated with adverse histo-
pathologic features. Expression of  biomarkers such PD-L1 may help better risk-stratify non-ccRCC patients to guide treatment decisions 
and follow-up strategies.
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Introduction
Renal cell carcinoma (RCC) is a lethal urologic malignancy 
accounting for 62,700 new cases and 14,240 deaths per year 
in the Unites States (1). Although diagnosis in earlier stages 
has become more frequent due to increased use of abdominal 
imaging, mortality rates have not decreased (2, 3). In cases 
of clinically localized disease, surgical resection remains the 
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mainstay of curative treatment although recurrences can 
occur in 20–40% of cases (4).
RCC is considered to be immuno-responsive with cases 
of complete regression reported with high-dose immunother-
apy (5). Newer treatments have mainly relied on the vascu-
lar endothelial growth factor (VEGF) or mammalian target 
of rapamycin (mTOR) pathways, although no durable re-
sponses have been observed to date (6, 7). Recent advances 
in the understanding of molecular contributors of RCC 
have led to the emergence of novel therapeutic agents such 
as immune checkpoint inhibitors (8). In 2015, Nivolumab, 
an anti-programmed cell death-1 (PD-1) inhibitor, was ap-
proved for patients with advanced clear cell RCC (ccRCC) 
with failed prior anti-angiogenic therapy due to significantly 
higher objective response rates and an acceptable toxicity 
profile (9, 10).
Despite exciting breakthroughs and increased knowledge 
of the immune response in RCC carcinogenesis, a significant 
proportion of patients with non-clear cell RCC (non-ccRCC) 
subtypes were excluded from pivotal clinical trials. This, in 
turn, limits the available data needed for the development 
of evidence-based recommendations. Thus far, the prognos-
tic value of programmed death ligand-1 (PD-L1) positivity 
in non-ccRCC remains unclear. In this study, we sought to 
examine the clinical significance of PD-L1 expression in a 
contemporary cohort of patients treated for non-ccRCC at 
a single institution.
Materials and Methods
Patient selection
A cohort of non-ccRCC patients treated between 2005 and 
2015 was retrospectively identified from our RCC database. 
Tissue was available for 45 patients with non-clear cell sub-
types. The study was approved by the institutional review 
board.
PD-L1 Immunohistochemistry (IHC)
Tissue microarray (TMA) blocks were prepared from 45 
non-ccRCC formalin-fixed paraffin-embedded (FFPE) speci-
mens. A hematoxylin and eosin (H&E) slide of each archival 
specimen was evaluated, and a block representing the over-
all tumor was chosen for TMA preparation. Three cores of 
1-mm diameter per case were selected and sections were cut 
into 4-µm thicknesses and placed on positively charged slides 
for immunostaining. For cases with sarcomatoid or rhabdoid 
features, only the non-clear cell component was evaluated. 
Slides were subjected to immunostaining using the Ventana 
Discovery XT automated system (Ventana Medical Systems, 
Tucson, AZ) using commercially available antibodies against 
PD-L1 (E1L3N; Cell Signaling Technology, Beverly, MA). 
PD-L1 expression was defined in tumor cells if  membranous 
alone or membranous and cytoplasmic staining was present. 
The positivity was further subclassified as ≥1, ≥5, ≥10, ≥25, 
and ≥50%. PD-L1 positivity of tumor cells was defined as 
≥1% of staining. This cutoff  level was based on published 
data showing successful anti-PD-1 therapy in patients with 
low PD-L1 expression (11). An expert in genitourinary pa-
thology (J.D.) completed this work and decided on IHC 
positivity.
There is no definitive cutoff  for PD-L1 positivity, with 
more than one threshold being reported for most antibodies 
in the literature. Published data for PD-L1 tests are mainly 
focused on immunohistochemistry tests for lung cancer. The 
variability in test cutoffs and standards for PD-L1 testing 
suggests that there is presently no standardized approach. 
Data on renal cell cancers are scarce. Hence, in this study we 
followed the approach that has been followed by many pub-
lished studies in the literature based on lung cancer where the 
cutoff  value of ≥1% for PDL-1 has been considered positive. 
According to Festino et al., there is no definitive threshold 
result that can be universally applied to predict clinical re-
sponse to PD-L1–targeted precision treatments (12).
Statistical analysis
The association between PD-L1 expression status and 
histopathologic characteristics was evaluated using the 
Mann–Whitney or chi-square test and Fisher’s exact test 
for numeric and categorical variables, respectively. Data 
were expressed as median and interquartile range (IQR) for 
continuous variables, and binary variables were reported as 
counts and percentages (%). Survival endpoints evaluated 
were cancer-specific survival (CSS) and recurrence-free sur-
vival (RFS) and were defined as the time from surgery to 
death from disease and recurrence of disease, respectively. 
CSS and RFS stratified by PD-L1 status were estimated 
using the  Kaplan–Meier method. Statistical significance was 
defined as P < 0.05. All statistical analyses were performed 
using Statistical Package for the Social Sciences (SPSS), 
 version 24.0 (IMB Corp, Armonk, NY).
Results
Clinicopathologic characteristics
Between 2005 and 2015, we identified 45 non-ccRCC patients 
with available tissue. Clinicopathologic characteristics are 
provided in Table 1. Median age was 58 years (IQR: 53–68.5). 
Of the patients, 13 (29%) underwent partial nephrectomy and 
32 (71%) underwent radical nephrectomy. Regional lymph 
node dissection was performed in seven (16%) patients, while 
inferior vena cava thrombectomy was completed in three 
(6.7%) patients. Histology subtypes included sarcomatoid 
RCC (n = 9), rhabdoid RCC (n = 6), medullary RCC (n = 2), 
Xp11.2 translocation RCC (n = 2), collecting duct RCC 
(n = 1), papillary type I RCC (n = 11), and papillary type II 
RCC (n = 14). Median tumor size was 7 cm (IQR: 4.5–12.3). 
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Table 1. Patients and tumor characteristics.
Patients characteristics (n = 45)
Median age, years (IQR) 58 (53–68.5)
Gender (%)
Male 34 (75.6)
Female 11 (24.4)
Race (%)
White 27 (60)
Non-white 18 (40)
Karnofsky Performance Scale (%)
<80% 8 (17.8)
≥80% 37 (82.2)
Surgical procedure (%)
Partial nephrectomy 13 (28.9)
Radical nephrectomy 32 (71.1)
Regional lymph node  dissection 7 (15.6)
IVC thrombectomy 3 (6.7)
Tumor characteristics (n = 45)
Non-clear cell subtypes (%)
Sarcomatoid RCC 9 (20)
Rhabdoid RCC 6 (13.3)
Medullary RCC 2 (4.4)
Xp11.2 translocation RCC 2 (4.4)
Collecting duct RCC 1 (2.2)
Papillary type 1 RCC 14 (31.1)
Papillary type 2 RCC 11 (24.4)
AJCC pathologic T stage (%)
pT1 16 (35.6)
pT2 6 (13.3)
pT3 21 (46.7)
pT4 2 (4.4)
AJCC clinical M stage (%)
cM0 39 (86.7)
cM1 6 (13.3)
Median tumor size, cm (IQR) 7 (4.5–12.3)
PD-L1 expression in non-clear cell RCC
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Approximately 51% of tumors were pT3–4 and 75.5% were 
Fuhrman nuclear grades 3–4.
PD-L1 expression and histopathologic characteristics 
in non-ccRCC
PD-L1 positivity on tumor cells was noted in nine (20%) 
 patients (Figure 1), including two papillary type 2 (18%), 
three sarcomatoid (33%), three rhabdoid (50%), and one 
Xp11.2 translocation tumors (50%). PD-L1 positivity 
was significantly associated with higher Fuhrman nu-
clear grade (P = 0.048) and perineural invasion (P = 0.043) 
(Table 2).  Although not statistically significant, patients with 
PD-L1-positive tumors had higher pT stage, more cM1 dis-
ease, greater tumor size, more lymphovascular invasion, and 
more tumor necrosis.
Table 1. (Continued )
Fuhrman nuclear grade (%)
I 3 (6.7)
II 8 (17.8)
III 19 (42.2)
IV 15 (33.3)
Adverse features (%)
Lymphovascular invasion 12 (26.7)
Tumor necrosis 23 (51.1)
Perineural invasion 1 (2.2)
Tumor thrombus 8 (17.8)
Surgical margin status
Negative 40 (88.9)
Positive 4 (8.9)
Unknown 1 (2.2)
PD-L1 expression status
<1% (negative) 36 (80)
≥1% (positive) 9 (20)
Figure 1. FFPE non-ccRCC specimens stained with anti-PD-L1 antibody (E1L3N). (A) Positive PD-L1 staining; 
≥50% positivity (20X). (B) Negative PD-L1 staining; <1% positivity (20X).
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Table 2. Association of PD-L1 expression and histopathologic characteristics in non-ccRCC.
Characteristic PD-L1(-) n = 36 PD-L1(+) n = 9 P value
AJCC pathologic (pT) (%)
pT1/2 19 (52.8) 3 (33.3)
0.252
pT3/4 17 (47.2) 6 (66.7)
AJCC clinical (cM) (%)
cM0 32 (88.9) 7 (77.8)
0.344
cM1 4 (11.1) 2 (22.2)
Median tumor size, cm (IQR) 7 (4.5–12.6) 8.5 (3.8–12.2) 0.865
Fuhrman nuclear grade (%)
I/II 9 (25) 2 (22.2)
0.048
III/IV 27 (75) 7 (77.8)
Lymphovascular invasion (%)
Negative 28 (77.8) 5 (55.6)
0.225
Positive 8 (22.2) 4 (44.4)
Perineural invasion (%)
Negative 36 (100) 8 (88.9)
0.043
Positive 0 (0) 1 (11.1)
Tumor necrosis (%)
Negative 18 (50) 3 (33.3)
0.303
Positive 18 (50) 6 (66.7)
No. Non-clear cell subtypes (%)
Sarcomatoid RCC 6 (66.6) 3 (33.3)
0.135
Rhabdoid RCC 3 (50) 3 (50)
Medullary RCC 2 (100) 0 (0)
Xp11.2 translocation RCC 1 (50) 1 (50)
Collecting duct RCC 1 (100) 0 (0)
Papillary type 1 RCC 14 (100) 0 (0)
Papillary type 2 RCC 9 (81.8) 2 (18.2)
Bold values indicate p<0.05.
PD-L1 expression and oncological outcomes in 
non-ccRCC
Median follow-up was 40 months (IQR: 22.9–72.5). Eleven 
(24.4%) patients had died of disease at the time of the anal-
ysis. Five-year CSS was 83 and 73% for PD-L1 negative and 
positive cases, respectively (log-rank P = 0.47) (Figure 2). 
Five-year RFS was 61.5 and 55.6% for PD-L1 negative and 
positive cases, respectively (log-rank P = 0.58) (Figure 3).
Discussion
Immunomodulatory agents targeting the PD-1/PD-L1 axis 
have revolutionized treatment of several malignancies, in-
cluding advanced RCC (10). Unfortunately, much of this 
progress has been limited to patients with ccRCC, partly due 
to the relative rarity of non-clear cell variants and the pau-
city of knowledge about the molecular and biologic drivers 
of disease. In this study, PD-L1 was expressed in a fifth of 
PD-L1 expression in non-clear cell RCC
Journal of Kidney Cancer and VHL 2018; 5(4): 6–13 11
Figure 2. Kaplan–Meier plots of cancer-specific survival (CSS) according to PD-L1 expression status in non-ccRCC patients.
Figure 3.  Kaplan–Meier plots of recurrence-free survival (RFS) according to PD-L1 expression status in non-ccRCC patients.
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non-ccRCC cohort while being associated with adverse his-
topathologic features.
PD-1 is a member of  the B7–CD28 family and serves 
as a cell surface inhibitory receptor on T cells (13, 14). 
Mechanisms of  action of  immune checkpoint inhibitors 
are nonspecific but generally lead to immune system ac-
tivation (6, 15). Expression of  PD-1 by tumor-infiltrat-
ing lymphocyte mononuclear cells (TIMC) and PD-L1 
on tumor cells has been associated with poor outcomes 
in several tumor types (15–19). Thompson et al. were one 
of  the first groups to demonstrate PD-L1 expression as a 
significant predictor of  cancer progression and mortality 
in ccRCC (20, 21).
To date, only two studies evaluating PD-L1 expres-
sion in non-ccRCC have been published. Choueiri et al. 
assessed PD-L1 expression in 101 non-ccRCC patients 
including chromophobe (n = 36), papillary (n = 50), col-
lecting duct (n = 5), and Xp.11.2 translocation (n = 10) 
variants (22). PD-L1 positivity on tumor cells (11 cases, 
10.9%) was significantly associated with higher stage and 
Fuhrman grade, and a worse overall survival. Similarly, 
our study revealed that PD-L1 positivity was associated 
with higher Fuhrman grade and perineural invasion, with 
a trend towards worse oncological outcomes. Conversely, 
Abbas et al. found no significant correlation between 
PD-1/PD-L1 expression and oncological outcomes in 63 
cases of  papillary, chromophobe, and sarcomatoid RCC 
variants (23).
Because of the lack of available treatments, studies com-
bining non-clear and clear cell carcinomas have focused on 
angiogenesis inhibitors (anti-VEGF) and other targeted 
therapies (mTOR inhibitors). A recent meta-analysis of 20 
studies including 1244 non-ccRCC and 6300 ccRCC patients 
revealed that the objective response rate to targeted therapy 
was significantly lower in those with non-clear cell subtypes 
(9.2% vs 14.8%) (24). Progression-free survival and over-
all survival were also shorter in non-ccRCC (7.5 and 13.2 
months) versus ccRCC patients (10.5 and 15.7 months). Fur-
ther studies with non-ccRCC cohorts are needed to assess 
the immune checkpoint therapy for expanding therapeutic 
options for these patients.
We acknowledge the several limitations of  this study, 
including inherent biases associated with its retrospective 
design, small sample size, and population heterogeneity. 
Although we correlated PD-L1 expression with oncologic 
outcomes, causality cannot be established. The limited 
number of  cases and events underpowered our analysis. 
Nevertheless, this is a common problem due to the rarity 
of  non-ccRCC and a main cause of  poor accrual in clin-
ical trials. Moreover, this study validates the findings of 
the only previous report showing a correlation between 
PD-L1 positivity and adverse histopathologic features in 
non-ccRCC.
Conclusion
PD-L1 is expressed in non-ccRCC and is associated with 
a more aggressive tumor phenotype. There was also a 
trend toward worse oncological outcomes in patients with 
PD-L1-positive tumors. Expression of biomarkers such 
PD-L1 may help better risk-stratify non-ccRCC patients to 
guide treatment decisions and follow-up strategies. Further 
investigation of anti-PD-1 and anti-PD-L1 immune check-
point inhibition in patients with non-ccRCC is warranted.
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